Progress in the characterization of slowly progressive autoimmune diabetes in adult patients (LADA or type 1,5 diabetes)

Experimental and Clinical Endocrinology and Diabetes

Volumn 109, Issue SUPPL. 2, 2001, Pages

  Schernthaner, G ^a   Hink, S ^a   Kopp, H P ^a   Muzyka, B ^a   Streit, G ^a   Kroiss, A ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

GAD; IA2; Insulin deficiency; Islet autoimmunity; LADA; Type 1.5 diabetes

Indexed keywords

AUTOANTIBODY; ENZYME ANTIBODY; GLUTAMATE DECARBOXYLASE;

ADULT; AGING; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE COURSE; GLUCOSE INTOLERANCE; HEREDITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; SEROPREVALENCE;

ADULT; AUTOIMMUNE DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE PROGRESSION; HUMANS; TIME FACTORS; WORLD HEALTH;

EID: 0034971563     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18573     Document Type: Article

References (39)

1. Definition, diagnosis and classification of diabetes mellitus and ist complications. Part I: Diagnosis and classification of diabetes mellitus. Provisorial Report of a WHO Consulation
2. Identification of the 64K auto-antigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase
3. Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins
4. GAD antibody negative NIDDM in black subjects with diabetic ketoacidosis and increased frequency of human leucocyte antigen DR 3 and DR4. Flatbush diabetes
5. Low prevalence of islet autoimmunity in adult diabetes and low predictive value of islet autoantibodies in the general adult population of northern Italy
6. Clinical, immunological, and genetic heterogeneity of diabetes in an Italian population-based cohort of lean newly diagnosed patients aged 30-54 years
7. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA)
8. Lack of antibodies to glutamic acid decarboxylase in young adults of the high diabetes prevalence Wanigela people of Papua New Guinea
9. Prediction of type 1 diabetes postpartum in patients with gestational diabetes by combined islet cell autoantibody screening: A prospective multi-center study
10. Increased risk for endocrine autoimmunity in Italian type 2 diabetes patients with GAD 65 autoantibodies
11. Beta-cell function in relation to Islet cell antibodies during the first 3 years after clinical diagnosis of diabetes in type II diabetic patients
12. Glutamate decarboxylase antibody levels predict rate of beta-cell decline in adult-onset diabetes
13. Islet cell antibodies and fasting plasma C-peptide during the first 10 years after diagnosis in patient with diabetes mellitus diagnosed in adult age
14. Genetic heterogeneity ofautoimmune diabetes: Age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group
15. Clinical and pathogenetic significance of pancreatic-islet-cell antibodies in diabetics treated with oral hypoglycaemic agents
16. Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA)
17. Type 1 1/2 Diabetes: Myth or Reality?
18. Antibody to the M® 65,000 isoform of glutamic and decarboxylase are detected in non-insulin-dependent diabetes in Japanese
19. Immunologically-related or incidental coexistence of diabetes mellitus and Graves disease; discrimination by anti-GAD antibody measurement
20. Type I diabetes masquerading as type II diabetes. Possible implications for prevention and treatment
21. Significance of GAD positivity in elderly patients with diabetes
22. Incidence of insulin-dependent diabetes mellitus in age groups over 30 years in Denmark
23. Five-year follow-up of islet cell antibodies in type 2 (non-insulin-dependent) diabetes mellitus
24. G.A.D. antibodies in NIDDM. Ten-year follow-up from the diagnosis
25. The low prevalence of immunogenic markers in Korean adult-onset IDDM patients
26. Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes
27. Emerging epidemic of type 2 diabetes in youth
28. Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus
29. Low prevalence of antibodies to GAD65 in a 50- to 74-year old general Dutch population. The Hoorn Study
30. The relation between clinical, immunological and genetic factors in insulin-dependent diabetes mellitus
31. Immunological heterogeneity in type I diabetes: Presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease
32. Anti-GAD antibodies in Chinese patients with youth and adult-onset IDDM and NIDDM
33. Cyclosporin-induced remission of IDDM after early intervention: Association of I yr of cyclosporin treatment with enhanced insulin secretion
34. Impaired insulin secretion in non-diabetic offspring of probands with latent autoimmune diabetes mellitus in adults
35. Gender, autoantibodies, and obesity in newly diagnosed diabetic patients aged 40-75 years
36. GAD antibodies in elderly men in different categories of glucose tolerance
37. Latent autoimmune diabetes mellitus in adults (LADA): The role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency
38. Diabetes epidemiology as a tool to trigger diabetes research and care
39. Crucial points at diagnosis - NIDDM or slow IDDM